Development of the Guideline for Management of Amlodipine Induced Gingival Overgrowth in Hypertensive Patients
Article Sidebar
Main Article Content
Abstract
Objectives: To establish the guidelines for following, monitoring, preventing, and managing amlodipine induced gingival overgrowth (AIGO). Methods: The study employed mixed methodology of both qualitative and quantitative. The researchers compared 152 patients taking amlodipine (study group) and 147 patients taking others anti-hypertensive medications (comparison group). The study examined oral hygiene and gingivitis using the OHI-S and the Bokenkamp et al.’s criteria, respectively. A dentist, who was blinded to the group subjects belonging to, was the examiner in both groups. The study assessed oral health quality of life by using the Oral Impact on Daily Performance (OIDP). The researchers developed the guidelines to follow, monitor, prevent, and manage AIGO by applying concept mapping. Results: Prevalence of GO was 12.50 and 4.76% in the study group and comparison group, respectively (OR=3.04, 95% CI=1.12-8.20, P=0.018). Smoking, and calculus index were significantly associated with GO. The guideline for management of AIGO in hypertensive patients consisted of 1) setting of clear policy 2) creating knowledge for multidisciplinary team 3) strong multidisciplinary team 4) having quality service for AIGO and 5) proactively improving to prevent the problem Conclusion: The prevalence of AIGO was 12.50%. The guideline for management of AIGO should consist of 5 dimensions identified in the study.
Article Details
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
2. World Health Organization. Promoting rational use of medicines: core components. WHO Policy Perspec- tives on Medicines. Geneva. 2002.
3. Anon. Service plan: Rational drug use (RDU) [online]. 2016 [cited Dec 9, 2016]. Available from: www.hfocus .org/content/2016/07/12427.
4. Muenpa R, Puripunyavanich N. Rational drug use. ) [online]. 2016 [cited Jan 19, 2017]. Available from: ccpe.pharmacycouncil.org/index.php?option=article_detail&subpage=article_detail&id=209
5. Food and Drug Administration. Rational use of drugs: Problems and related factors. Nonthaburi: Ministry of Public Health; 2016.
6. Ministry of Public Health. Service plan: Rational drug use [online]. 2016 [cited Dec 9, 2016]. Available from: www.lpnh.go.th/drug/file/Manual_Service%20Plan%20RDU_Sept2016.pdf.
7. Sanjeev J, Sucheta B. A rare case report of amlodipine-induced gingival enlargement and review of its pathogenesis. Case Rep Dent. 2013; 2013:138248. doi: 10.1155/2013/138248.
8. Aldemir NM, Begenik H, Emre H, Erdur FM, Soyoral Y. Amlodipine-induced gingival hyperplasia in chronic renal failure: a case report. Afr Health Sci. 2012; 12: 576-8.
9. Madi M, Shetty SR, Babu SG, Achalli S. Amlodipine-induced gingival hyperplasia–A case report and review. West Indian Med J. 2015;64:279.
10. Livada R, Shiloah J. Calcium channel blocker-induced gingival enlargement. J Hum Hypertens. 2014; 28:10-4.
11. Katzung BG. Vasodilator and the treatment of angina pectoris. In: Katzung BG , Masters SB, Trevor AJ, editors. Basic and clinical pharmacology. 12th ed. New York: The McGraw-Hill; 2007. p. 193-210.
12. Golan DE, Tashjian AH. Principle of cardiovascular pharmacology. In: Williams L, Wilkin L, editors. Principle of pharmacology. New York; 2008. p. 368-70, 377-9.
13. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodon tol. 1999;4:1-6.
14. The American Academy of Periodontology. Glossary of Periodontal Terms. 4th ed. Chicago: The American Academy of Periodontology; 2001.
15. Srivastava AK, Kundu D, Bandyopadhyay P, Pal AK. Management of amlodipine-induced gingival enlarge ment: Series of three cases. J Indian Soc Periodontol. 2010; 14: 279–81.
16. Hassell TM, Hefti AF. Drug-induced gingival over growth: old problem, new problem. Crit Rev Oral Biol Med 1991;2:103-37.
17. Mishra MB, Khan ZY, Mishra S. Gingival overgrowth and drug association. J Acad Med Sci. 2012.2; 91-6.
18. Gosavi DD, Nanotkar S, Suman A. Drug induced gingival enlargement. Int J Pharmaceut Appl. 2013; 4: 43-8.
19. Brown RS, Arany PR. Mechanism of drug-induced gingival overgrowth revisited: a unifying hypothesis. Oral Dis. 2015; 21: e51–e61.
20. Health Product Vigilance Center. Spontaneous report of adverse drug reaction 2008. Nonthaburi. Food and Drug Administration, Ministry of Public Health, 2008: p. 51-4.
21. Health Product Vigilance Center. Spontaneous report of adverse drug reaction 2010. Nonthaburi. Food and Drug Administration, Ministry of Public Health, 2010: p. 98-107.
22. Health Product Vigilance Center. Spontaneous report of adverse drug reaction 2011. Nonthaburi. Food and Drug Administration, Ministry of Public Health, 2011: p. 76.
23. Health Product Vigilance Center. Spontaneous report of adverse drug reaction 2012. Nonthaburi. Food and Drug Administration, Ministry of Public Health, 2014: p. 115.
24. Health Product Vigilance Center. Spontaneous report of adverse drug reaction 2013. Nonthaburi. Food and Drug Administration, Ministry of Public Health, 2014: p. 85-6.
25. Health Product Vigilance Center. Spontaneous report of adverse drug reaction 2014. Nonthaburi. Food and Drug Administration, Ministry of Public Health, 2014: p. 91-2.
26. Health Product Vigilance Center. Spontaneous report of adverse drug reaction 2015. Nonthaburi. Food and Drug Administration, Ministry of Public Health, 2016: p. 108-9.
27. Health Product Vigilance Center. Spontaneous report of adverse drug reaction 2016. Nonthaburi. Food and Drug Administration, Ministry of Public Health, 2017: p. 120.
28. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodon tol 1999;4:1-6.
29. Jorgensen MG. Prevalence of amlodipine-related gingival hyperplasia. J Periodontol 1997;68: 676-8.
30. Ellis JS, Seymour RA, Steele JG, Robertson P, Butler TJ, Thomason JM. Prevalence of gingival overgrowth induced by calcium channel blockers: A community-based study. J Periodontol 1999; 70:63-7.
31. Ono M, Tanaka S, Takeuchi R, Matsumoto H, Okada H, Yamamoto H, et al. Prevalence of amlodipine-induced gingival overgrowth. Int J Oral-Med Sci 2010; 9: 96-100.
32. Karnik R, Bhat KM, Bhat GS. Prevalence of gingival overgrowth among elderly patients under amlodipine therapy at a large Indian teaching hospital. J Gero dontol 2012; 29: 209-13.
33. Livada R, Shiloah J. REVIEW Calcium channel blocker-induced gingival enlargement. J Hum Hyper tens 2014;28,10–4.
34. Jose J, Santhosh YL, Naveen MR, Kumar V. Case report of amlodipine induced gingival hyperplasia late onset at a low dose. Asian J Pharm Clin Res. 2011; 4: 5–6.
35. Wisetsing C, Niwatananun K, Ruengorn C. Preva lence of gingival enlargement and associated with amlodipine. Thai Pharmaceutical and Health Science Journal. 2014; 9: 17-25.
36. Bokenkamp A, Bohnhorst B, Beier C, Albers N, Offner G, Brodehl J. Pediatric nephrology. Pediatr Nephro. 1994;8:181–5.
37. Wei SH, Lang NP. Periodontal epidemiological indices for children and adolescents: II. Evaluation of oral hygiene; III. Clinical applications. Pediatr Dent. 1982; 4: 64–73.
38. Greene JC, Vermillion JR. The simplified oral hygiene index. J Dent Assoc. 1964;68:7–13.
39. Adulyanon S, Sheiham A. Oral Impacts on Daily Performances. In: Slade GD, editor. Measuring oral health and quality of life. North Carolina: Chapel Hill; 1997. p. 151-60.
